Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus gasseri LBV150
- Development stage
- Unknown
- Lead developer
- Precision Biotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal
01
Overview
Lactobacillus gasseri LBV150 is a specific strain of *Lactobacillus gasseri*, a Gram-positive, lactic acid-producing bacterium commonly found in the human vaginal and gastrointestinal microbiome. This strain is recognized for its probiotic activity, maintaining microflora balance in the vagina and gut through inhibition of pathogenic bacteria such as *Gardnerella vaginalis*, *Candida albicans*, *Escherichia coli*, and *Salmonella enteritidis*[1][3]. Mechanistically, it exerts its effects by producing lactic acid, hydrogen peroxide, and bacteriocins, which inhibit pathogen growth, as well as by strong adhesion to epithelial cells that outcompete pathogen colonization[1][3]. It is administered for restoring vaginal microflora following bacterial vaginosis, and potentially for gut health, constipation, and prevention/treatment of vaginitis. The strain is considered safe and is available for both oral and vaginal administration[1][2][4].
- Brand names
- lactobacillus gasseri LBV150
- Other names
- lactobacillus gasseri LBV150
Beyond the preview
Go deeper on lactobacillus gasseri LBV150.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus gasseri LBV150.